Geron

Geron Total Assets

The Total Assets of Geron (GERN) as of Nov 7, 2026 is 570.54 M USD. In the previous year, Total Assets was 593.78 M USD — a change of -3.91% (lower).

Total Assets

570.54 MUSD

YoY

-3.91%

Last updated:

Total Assets of Geron is 2025 570.54 M USD. Total Assets of Geron was 2024 593.78 M USD. It decreases by -3.91% lower compared to the previous year.

The Geron Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2018
185.28 M USD
Jan 1, 2019
165.52 M USD
Jan 1, 2020
270.73 M USD
Jan 1, 2021
226.03 M USD
Jan 1, 2022
190.58 M USD
Jan 1, 2023
394.08 M USD
Jan 1, 2024
593.78 M USD
Jan 1, 2025
570.54 M USD
The Geron Total Assets history
YEARTotal AssetsYoY
570.54 MUSD-3.91%
593.78 MUSD+50.68%
394.08 MUSD+106.78%
190.58 MUSD-15.69%
226.03 MUSD-16.51%
270.73 MUSD+63.57%
165.52 MUSD-10.67%
185.28 MUSD+67.96%
110.31 MUSD-15.31%
130.25 MUSD-12.44%
148.76 MUSD-13.77%
172.51 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Geron Stock analysis

What does Geron do? Geron Corp is a biopharmaceutical company headquartered in Menlo Park, California, founded in 1990. The company's goal is to develop innovative products and therapies that have the potential to combat serious diseases. Geron Corp specializes in the research of embryonic stem cells. The company is a pioneer in researching technologies for the use of stem cells and has made significant breakthroughs in the field of regenerative medicine. By developing new stem cell therapies, Geron Corp aims to improve the lives of patients with serious conditions such as cancer, Parkinson's disease, and spinal cord injuries. Geron Corp operates various business segments, including oncology, regenerative medicine, and RNA-based therapies. In the field of oncology, the company focuses on developing therapies for the treatment of cancer, particularly solid tumors. One of the most important developments is the drug Imetelstat, which aims to extend the telomeres of cancer cells by inhibiting the activity of telomerase. Imetelstat is currently in various clinical trials and has the potential to revolutionize the treatment of leukemia and other types of cancer. Another important business segment of Geron Corp is regenerative medicine, particularly the research of therapies for repairing spinal cord injuries. The company has made significant breakthroughs in this area and has a promising pipeline of products aimed at repairing damaged nerve cells in the spinal cord and restoring patients' mobility. Geron Corp is also a leading company in the field of RNA-based therapies. RNA-based therapies aim to regulate gene activity to treat diseases. The company has developed various innovative technologies aimed at accelerating and enhancing the development of RNA-based therapies. In recent years, Geron Corp has brought a variety of products to the market, including drugs for the treatment of spinal cord injuries, leukemia, and other types of cancer. The company has also formed partnerships with other leading companies in the biopharmaceutical industry to advance the development and commercialization of products. Overall, Geron Corp has made a significant contribution to the research and development of new technologies and therapies with the potential to improve the lives of millions of people. The company has a promising pipeline of products and is committed to further solidifying its position as a leading company in the biopharmaceutical industry. Geron is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Geron stock

Total Assets of Geron is 570.54 M USD in 2025.

Total Assets of Geron changed from 593.78 M USD to 570.54 M USD, representing a -3.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets Geron since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's Geron historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Geron

All Key Metrics — Geron